CM Life Sciences II Inc.
Completed 2021-09-01- CIK 1837412
- CMII
- Now SLGC
- IPO 2021-02-24
- $276M trust
- 299 filings
Successfully merged with SomaLogic, Inc. • Now trading as SLGC
- IPO Size
- $276M
- raised at the IPO
- Trust
- $276M
- as of 2021-06-30
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2021
- year it listed
Filings, by quarter
299 filings over 18 quarters; violet bars carry a milestone
- 20 Q4: 1 filing
- 21 Q1: 19 filings
- 21 Q2: 11 filings
- 21 Q3: 43 filings
- 21 Q4: 24 filings
- 22 Q1: 21 filings
- 22 Q2: 8 filings
- 22 Q3: 14 filings
- 22 Q4: 18 filings
- 23 Q1: 24 filings
- 23 Q2: 26 filings
- 23 Q3: 5 filings
- 23 Q4: 49 filings
- 24 Q1: 35 filings
- 24 Q2: 0 filings
- 24 Q3: 0 filings
- 24 Q4: 0 filings
- 25 Q1: 1 filing
- S-1 filed 20 Q4
- IPO 21 Q1
- Definitive agreement 21 Q1
- Completed 21 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
CM Life Sciences II Inc. is a blank-check company seeking an initial business combination, with a stated focus on the life sciences sector. It will leverage its team's life-sciences and investment experience to identify a suitable business combination target.
Investment Focus
Biopharmaceuticals, Healthcare
Key Information
As the filings state it
- IPO Date
- 2021-02-24
- Total Redemptions
- $8.1M
- PIPE
- $365M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2021-09-01
- Merger Target
- SomaLogic, Inc.
- SPAC Ticker
- CMII
- Merged Ticker
- SLGC
Stock Performance
SLGCTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2026-07-17 | $10.10 | |
| 6 Months Post-Merger | 2026-07-17 | $10.06 | 0% |
| 1 Year Post-Merger | 2026-07-17 | $10.06 | 0% |
| 2 Years Post-Merger | 2026-07-17 | $10.06 | 0% |
| Current Price | 2026-09-03 | $10.05 | -0% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The sponsor is affiliated with Eli Casdin of Casdin Capital and Keith Meister of Corvex Management. Their backgrounds include life-sciences and healthcare investing, public-company leadership and board experience, and investment management. The named officers and director nominees include leaders and specialists from life sciences, diagnostics, biotechnology and investment management.